Sanofi is already a player in the hemophilia A market, but the company is developing another therapy that could better match up against a blockbuster product from rival Roche. The experimental ...

The US Food and Drug Administration on Tuesday approved Hemgenix, a new drug to treat hemophilia. Manufacturer CSL Behring set the price at $3.5 million per treatment, making it the most expensive ...

A gene-based therapy is potentially a step closer to becoming a one-time treatment for men with hemophilia. The life-threatening genetic disorder hinders the body’s ability to form blood clots.

Hemophilia and von Willebrand disease (VWD) are bleeding disorders that share similar symptoms. Both conditions make it more difficult for the blood to clot. Both conditions can also be genetic ...

Black patients with hemophilia A (factor VIII deficiency ... patients were obtained from review of the patients' medical charts. We used multivariable logistic regression to control for these ...